GMP Services – Biotechnological Products and ATMPs


Process Validation

Manufacturers of pharmaceutical products are legally obliged to comply with Good Manufacturing Practice (GMP). The objective of GMP is to follow quality standards to ensure the safety, efficacy and quality of medicinal products.

The origin of GMP goes back to the USA of 1883, when the first recommendations for “Food and Drugs” were introduced under the direction of Harvey W. Wiley who, at that time, investigated food preservatives.

Noteworthy incidents have paved the way towards regulations and modern quality standards. Tetanus contaminated diphtheria vaccines, that caused numerous deaths, led to the Biologics Control Act of 1902. The unsatisfactory conditions of Upton Sinclair’s meat-packaging led to the Meat Inspection Act of 1907.

The Sulfanilamide tragedy followed in 1937 that caused the deaths of more than 100 people (mostly children) after using a drug that was clearly unsafe, led to the Federal Food, Drug and Cosmetic Act (FDC Act) of 1938. Last but not least, the Cutter incident in the 1950s (a failed process step of inactivating living polio virus) caused over 40.000 polio infected patients and, subsequently, the abrogation of the first mass vaccination program.

Due to failed quality controls at that time, an obviously clearly unsafe polio vaccine was used. All this has led to regulations and incorporation of quality standards into drug manufacturing and their control, that have come to be known as today’s GMP.

GMP Services

GMP Expertise

  • Manufacturing of Biotechnological Products
  • Manufacturing of Gene and Cell-based Therapy (ATMPs)
  • Cell and Molecular Biology
  • Quality of Biotechnological Products
  • Specification of Biotechnological Product
  • Pharmaceutical Quality System
  • Quality Risk Management
  • Data Integrity and Computerized Systems (CS)
  • European Commission’s Guide to GMP
  • ICH Quality Guidelines
GMP Expertise